FREMONT, Calif., June 29 /PRNewswire-FirstCall/ —
Vermillion, Inc. (Pink Sheets: VRML), a molecular diagnostics
company, today announced that the United States Patent and
Trademark Office (USPTO) has issued a notice of allowance of a
patent entitled “Biomarkers for Alzheimer’s disease” to the
Company. The patent claims are directed to biomarker combinations
for the diagnosis and management of Alzheimer’s disease and to the
measurement of the biomarkers by a variety of methods, including
mass spectrometry and immunoassay.
“The granting of our Alzheimer’s disease biomarker patent is
additional validation of our approach to intellectual property
protection. We view the increasing breadth of our patent portfolio
as a significant corporate asset,” said Gail S. Page, CEO and Chairperson.
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help
physicians diagnose, treat and improve outcomes for patients.
Vermillion, along with its prestigious scientific collaborators,
has diagnostic programs in oncology, hematology, cardiology and
women’s health. Vermillion is based in Fremont, California. Additional
information about Vermillion can be found on the Web at www.vermillion.com.
About OVA1™
OVA1(TM) is a qualitative serum test that combines the results
of five immunoassays into a single numerical score. It is indicated
for women who meet the following crite
‘/>”/>
